ERBB2 and breast cancer: Because of the high proportion of HR + tumors in HER2-low breast cancer, to avoid the influence of HR status on HER2-low subtype, we analyzed clinicopathological features divided by HER2 status of primary breast cancer within the HR + and HR-negative (HR−) subtypes (Table 1).